CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 11 enrolled
Drug / intervention
Ranolazinedrug
Likely dose
Ranolazine 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01174173
NCT01174173Phase 3Completed
CompareCT.gov

Effects of Ranolazine in Patients With Angina Due to Right Ventricular Ischemia in Pulmonary Arterial Hypertension

Northwestern University·interventional·Posted Aug 3, 2010·Updated May 11, 2018

In Brief

A Phase 3 clinical trial evaluating Ranolazine for Angina and Pulmonary Arterial Hypertension. Completed, enrolled 11 participants across 1 site.

Detailed Summary

The purpose of the study is to determine if the medication, ranolazine (study drug), can help improve blood flow to your heart, increase your exercise capacity and improve your quality of life (QOL). For this study, you will be asked to perform several tests in order to determine if your heart function, exercise capacity, chest pain and QOL have improved after 3 months of treatment with ranolazine. Ranolazine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of angina.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAngina, Pulmonary Arterial Hypertension
CountriesUnited States
CollaboratorsGilead Sciences

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 3, 2010
Enrollment StartJun 1, 2010
Primary CompletionJan 1, 2014
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 15.9 years ago

Interventions

Ranolazinedrug

ranolazine 1000 mg PO BID for 3 months